Background: Recent studies have suggested that there has been an increase in the number of 'warning letters' Abstract issued by the US Food and Drug Administration (FDA) despite the publication of the FDA advertising guidelines. However, limited information is available on the description of warning letters. The objective of this study was to analyse the frequency and content of FDA warning letters in relation to promotional claims and discuss the influence of regulatory and industry constraints on promotion. Methods: All warning letters published by the FDA between 5 May 1995 and 11 June 2007 were reviewed. Warning letters related to promotional issues were included and analysed. Information related to the identification number, date of the warning letter, FDA division that issued the letter, drug name, manufacturer, specific warning problem, type of promotional material and requested action was extracted. Two independent investigators reviewed and classified each PDF file, any differences were discussed until a consensus was reached. Results: Between May 1995 and June 2007 a total of 8692 warning letters were issued, of which 25% were related to drugs. Of these, 206 warning letters focused on drug promotion and were included in this study: 23% were issued in 2005, 15% in 2004 and 14% in 1998. In total, 47% of the warning letters were issued because of false or misleading unapproved doses and uses, 27% failed to disclose risks, 15% cited misleading promotion, 8% related to misleading labelling and 3% promoted false effectiveness claims. Discussion: There is an important variation in the number of warning letters issued in the last decade, probably because of the increasing number of drugs approved by the FDA, drug withdrawal scandals, and the publication of the FDA and the Pharmaceutical Research and Manufacturers of America (PhRMA) guidelines. Conclusion: We found that benefit-related claims, such as unapproved uses or doses of drugs, and failure to disclose risks, are the main causes of FDA issued warning letters for promotional claims related to medications.
Background
not have the authority to require sponsors to submit promotional materials for approval prior to use. [4, 5] Therefore, the FDA freSince 1962, the US Food and Drug Administration (FDA) has quently sees promotional materials only after they have been been charged with the responsibility of regulating prescription released or broadcast. [6] drug advertising and labelling. [1] The regulations include reviewOnce an advertisement is disseminated that is deemed to coning written, printed or graphic material accompanying a regulated tain a prohibited message, the FDA can require corrective actions product ('promotional labelling'), materials published in journals by means of untitled letters, warning letters, injunctions and conand newspapers, and information distributed via broadcast and telephone communications systems. [2, 3] However, the FDA does sent decrees, referrals for criminal investigation, or prosecution and seizures. [6] 'Warning letters' are notices issued by the FDA Inclusion/Exclusion Criteria when there are serious violations (such as repetitive misconduct) In the first review, the subject of each warning letter was or a potential for serious health risks to the public; 'untitled letters ' analysed and letters not related to drugs in humans (e.g. food, are issued for less serious violations.
animal products, etc.) were excluded. Then, PDF files of the These notices usually require the sponsor to discontinue use of remaining letters were downloaded and reviewed. Letters related the false or misleading advertising materials. Warning letters to drug manufacturing, clinical investigators, natural products (e.g. contain a statement that failure to respond may result in further herbs) or nondrug-related issues were subsequently excluded. regulatory action and the FDA can initiate court proceedings for Only PDF files of warning letters related to prescription or overseizure, injunction, or criminal prosecution. [4] Therefore, when the-counter (OTC) medications that were focused on promotional manufacturers receive a warning letter, they are supposed to claims were included in the study, irrespective of the issue date or correct the problem immediately and disseminate the correct mesthe issuing office (figure 1). sage using mailings and journals. However, a previous study [7] Data Extraction and Analysis showed that the FDA enforcement actions against false and misleading drug advertisements declined in 2002 and that there were Information extracted from the warning letters included identialso delays in enforcement actions. [7] [8] [9] [10] [11] [12] fication number, date of the warning letter, FDA division that Limited information is available on the content of FDA warnissued the letter, drug name, manufacturer, specific warning probing letters. Therefore, the objective of this study was to describe lem, type of promotional material and requested action. Two the number, type and content of warning letters for medications in investigators independently reviewed each PDF file and any difrelation to promotional claims, and to discuss the influence of ferences were discussed to reach a consensus (Salas and McCall). regulatory and industry constraints on promotion.
The type of warning was classified using the original wording of the letters and they include:
• unapproved doses and uses
Methods
• failure to disclose risks • misleading promotion Excel spreadsheets of both databases were downloaded and reviewed independently by two investigators (Salas and McCall). Only the content of warning letters related to medications was analysed; warning letters with an unclear subject or nonspecific warning information were also downloaded and analysed. labelling' included all labelling-related letters without specificarelated to devices, 35% (2970) were focused on food, 21% (1782) tion of the type of false labelling. The original letters did not define were related to manufacturing issues and 6% (509) related to the terms 'label', 'promotion' or 'advertising', but they reported to animal products and other nonprescribing drug-related issues (figbe based on the Food, Drug and Cosmetic Act (FD&C Act) of ure 2). Most of the warning letters were excluded in the first 1938. According to Section 502(n) of the FD&C Act, 'advertising' review but 24% required a second review because the reason for is considered to be messages published in journals, magazines, the warning was unclear. other periodicals and newspapers, or broadcast through media A total of 206 warning letters were included in the study, with such as radio, television and telephone communications systems, the highest number of letters issued for medications in 2005 (23% as well as computer programs, fax machines or electronic bulletin of all letters), followed by 2004 (15%) and 1998 (14%) [ figure 3 ]. boards. 'Labelling' means all labels and other written, printed or
In some years, many warning letters were issued for only one graphic matter accompanying a drug article. [10] medication because the drug was manufactured by various drug Some warning letters had more than one warning and, if that companies. For example, in 2002, 72 warning letters were issued occurred, each warning was coded separately. For example, if the for guaifenesin while in 2007, 21 warning letters were issued for warnings were "the promotional material makes unsubstantiated ergotamine. superiority claims and fails to reveal important risk information", As expected, most of the warning letters were issued by the the warning letter was coded as false effectiveness claims and also main offices at the FDA (85%), the Division of Drug Marketing, as failure to disclose risks.
Advertising and Communications (DDMAC) and the Center for Descriptive statistics such as percentages and frequencies were Drug Evaluation and Research (CDER). FDA local district offices used to analyse warning letters information. We analysed the issued the remainder of the warning letters. absolute number of warning letters, the number of unique medicaIn terms of content, most of the warning letters included general tions involved, the issuing office and the total number and type of statements about violations, such as lacking fair balance between violatory issues. benefits and risks. From our analysis of the violations, it was To analyse the type of warnings issued in letters per year, we stratified the dataset by annual periods starting on 1 May and ending on 30 April of each year. For example, in the year 1996, the starting date was 1 May 1995 and the end date was 30 April 1996. We then estimated the percentage of type of warning letters per year, classified by violatory issue.
Results
There were a total of 8692 warning letters issued between pectorants (37%), analgesics (10%), hair loss agents (2%), anaesthetics (1%), hormones (1%), smoking cessation therapies (1%) and antidiabetic drugs (1%) [ figure 5 ]. In 63% of the warning letters there were no details about the promotional material. Of the rest (38%), the misleading information was published in websites, medical journals, television advertisements, brochures, sales aids and 2% involved drug representatives directly (figure 6).
Discussion
Our study found that half the warning letters were issued because of benefit-related claims, particularly the promotion of drugs for unapproved (nonFDA approved) 'off-label' indications or unapproved doses. Health professionals can legally use drugs for off-label indications but it is prohibited for manufacturers to evident that benefit-related claims (unapproved dose, use and false promote drugs for these indications. So, a question that can be effectiveness or superiority claims) comprised half of the problem, raised is why do manufacturers promote off-label indications? while a third of the letters were related to safety issues. The Presumably, they do so to enlarge the size of the market for a given specific problems included: false or misleading unapproved doses drug, and to increase their sales and profit. [11] [12] [13] The recent case of and uses (47%), failure to disclose risks (27%), misleading promogabapentin (marketed as Neurontin ® 1 ) and the publication of its tion (15%), false labelling (8%) and false effectiveness claims internal marketing and promotional plans [14, 15] has opened many (3%). In the last decade, the promotion of unapproved doses or questions related to the off-label use of medications, particularly uses of drugs has been one of the main reasons to issue warning the marketing strategies used by manufacturers. Another such letters, which reached a peak in 2002. In 2006, the highest percentexample is oxycodone. [16] age of warning letters were issued because of failure to disclose
We found two peaks of warning letters issued during the period risks (figure 4).
1996-2007. The first peak occurred in 1998, when the number of There was a wide variation in the drugs involved in the issued warning letters relating to broadcast advertisements increased letters: 35% to guaifenesin, 10% to ergotamine, 2% progesterone, considerably, probably as a consequence of the publication of the and more than 50% to other drugs. The most frequent approved 1997 FDA draft guidance, which clarified and offered examples of classes of drugs mentioned in the warning letters were exadvertising regulations, mainly direct-to-consumer advertising. [17] [18] In these guidelines the FDA did not object to the use of the approved patient labelling for promotion, as long as the labelling was reprinted in full, communicated in lay language and included drugassociated risks. [6] The increase in the number warning letters issued after 2002 might also be a consequence of the number of drugs approved by the FDA. was 72. [19] Interestingly, since 2005 fewer warning letters have been isprofessionals such as journals, brochures and sales aids. However, sued, which may reflect the lessons learnt from the rofecoxib the warning letters did not describe how those materials were scandal in 2004, [20] increasingly stringent FDA requirements, [21] distributed to health professionals; it is possible that drug reprereduction in the number of new chemical entities approved by the sentatives were involved in that process. In recent years, the role of FDA [22] and as a consequence of the Pharmaceutical Research and drug representatives has become more controversial because some Manufacturers of America (PhRMA) guidelines. The PhRMA professionals argue that drug representatives provide unbalanced guidelines were issued in November 2005 to guide manufacturers information about the efficacy and safety of drugs, [24, 25] while on the principles of prescription drug advertising. Over the next others feel that they improve the quality of prescriptions by few years, it is possible that fewer FDA warning letters may be presenting up-to-date information on new products. [26] [27] [28] Universiissued because of the expiration of patent protection for 52 major ties such as Stanford University School of Medicine in California drugs in the period 2007-11 and the recent issuance of the FDA and the University of Pennsylvania School of Medicine have draft guidelines regarding the distribution of journal articles menbanned drug representatives from their facilities. [29, 30] This positioning unapproved uses of drugs. [19, 23] tion is questioned by some since banning drug representatives We found that 2% of warning letters involved drug representamight prevent students and residents from learning how to differtives directly, and 17% contained promotional material for health entiate unbiased from biased information. The alternative to banning drug representatives from universities might be to better educate students about promotional activities and strategies so that they are better able to respond to pharmaceutical marketing campaigns.
Interestingly, there was a high number of warning letters concerning OTC drugs, which might reflect the large number of OTC drugs available in the US market (>100 000), [31] the increase in the number of new OTC medications approved for marketing between 1995 and 2002 (95 in total) [32] or the closer FDA supervision of promotional materials for OTC medications, especially their doses and indications for uses. [33, 34] As we expected, most of the warning letters were issued by the central FDA office, but it is important to note the role that FDA local district offices play in the production of warning letters related to promotional activities of manufacturers. The activities of the local authorities has been more relevant in recent years when a series of scandals have been published for drugs approved and Conclusions promoted through direct-to-consumer advertising. [35] [36] [37] In conclusion, benefit-related claims such as unapproved uses From a consumer and prescriber perspective, one might wonder or doses of drugs, and failure to disclose risks are the main causes how the reporting system for unlawful promotional activities of FDA warning letters. The number of warning letters can fluctucould be improved. According to the FDA, the public can particiate quite dramatically from year to year and may reflect the pate in reporting the unlawful promotion of medications. For introduction of new advertising guidelines and regulations or other example, anyone can contact the State Board of Pharmacy to market forces. Further research would be needed to clarify the notify them of problems related to the dispensing and sales pracinfluence of these and other factors on promotional misconduct. tices of pharmacies, a website that illegally sells human drugs 2 , or e-mails that illegally promote medical products.
[38] However, it is
